Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Novakand Pharma AB's enterprise value is €-4.18 Mil.
Novakand Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.70 Mil. Therefore, Novakand Pharma AB's EV-to-EBITDA for today is 1.55.
The historical rank and industry rank for Novakand Pharma AB's EV-to-EBITDA or its related term are showing as below:
FRA:3EE0'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -34.84 Med: -3.82 Max: 1.36
Current: 1.36
During the past 13 years, the highest EV-to-EBITDA of Novakand Pharma AB was 1.36. The lowest was -34.84. And the median was -3.82.
FRA:3EE0's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 14.4
vs FRA:3EE0: 1.36
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Novakand Pharma AB (FRA:3EE0) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Novakand Pharma AB's PE Ratio (TTM) for today is calculated as:
Novakand Pharma AB's share price for today is €0.0001.
Novakand Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.036.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Novakand Pharma AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3EE0 vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Novakand Pharma AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novakand Pharma AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novakand Pharma AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Novakand Pharma AB's EV-to-EBITDA falls into.
Novakand Pharma AB's current Enterprise Value is €-4.18 Mil.
Novakand Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novakand Pharma AB (FRA:3EE0) has a EV-to-EBITDA of 1.55 as of Aug. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Novakand Pharma AB.
Is Novakand Pharma AB's EV-to-EBITDA too high?
Novakand Pharma AB's current EV-to-EBITDA is 1.55. The Biotechnology industry median EV-to-EBITDA is 14.40. Novakand Pharma AB's value of 1.55 is 89.2% below this industry median.
How does Novakand Pharma AB's EV-to-EBITDA compare to VRTX and REGN?
Novakand Pharma AB's EV-to-EBITDA of 1.55 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBITDA is 14.40. Novakand Pharma AB's value of 1.55 is 89.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.40, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novakand Pharma AB's current EV-to-EBITDA of 1.55 is 89.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Novakand Pharma AB. For the Biotechnology industry, the median EV-to-EBITDA is 14.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novakand Pharma AB's current EV-to-EBITDA is 1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novakand Pharma AB stock overvalued right now?
Novakand Pharma AB (FRA:3EE0) has a current EV-to-EBITDA of 1.55. The current EV-to-EBITDA is 1.55 and 89.2% below the Biotechnology industry median of 14.40. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Novakand Pharma AB (FRA:3EE0), the current EV-to-EBITDA is 1.55 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Novakand Pharma AB is developing a new class of innovative drugs focusing on inflammatory diseases and cancer. The company is developing a new class of small molecule drugs that control disease promoting immune cells with precision, by targeting the fractalkine axis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3EE0 has been successfully added to your 
